These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36181471)

  • 1. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.
    Diene G; Angulo M; Hale PM; Jepsen CH; Hofman PL; Hokken-Koelega A; Ramesh C; Turan S; Tauber M
    J Clin Endocrinol Metab; 2022 Dec; 108(1):4-12. PubMed ID: 36181471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.
    Roof E; Deal CL; McCandless SE; Cowan RL; Miller JL; Hamilton JK; Roeder ER; McCormack SE; Roshan Lal TR; Abdul-Latif HD; Haqq AM; Obrynba KS; Torchen LC; Vidmar AP; Viskochil DH; Chanoine JP; Lam CKL; Pierce MJ; Williams LL; Bird LM; Butler MG; Jensen DE; Myers SE; Oatman OJ; Baskaran C; Chalmers LJ; Fu C; Alos N; McLean SD; Shah A; Whitman BY; Blumenstein BA; Leonard SF; Ernest JP; Cormier JW; Cotter SP; Ryman DC
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1696-1708. PubMed ID: 36633570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome.
    Salehi P; Hsu I; Azen CG; Mittelman SD; Geffner ME; Jeandron D
    Pediatr Obes; 2017 Jun; 12(3):221-228. PubMed ID: 27071367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
    McCandless SE; Yanovski JA; Miller J; Fu C; Bird LM; Salehi P; Chan CL; Stafford D; Abuzzahab MJ; Viskochil D; Barlow SE; Angulo M; Myers SE; Whitman BY; Styne D; Roof E; Dykens EM; Scheimann AO; Malloy J; Zhuang D; Taylor K; Hughes TE; Kim DD; Butler MG
    Diabetes Obes Metab; 2017 Dec; 19(12):1751-1761. PubMed ID: 28556449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome.
    Dykens EM; Miller J; Angulo M; Roof E; Reidy M; Hatoum HT; Willey R; Bolton G; Korner P
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive management of obesity in people with Prader-Willi syndrome.
    Nolan BJ; Proietto J; Sumithran P
    Endocrine; 2022 Jun; 77(1):57-62. PubMed ID: 35524875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability and change over time of weight and BMI among adolescents and adults with Prader-Willi syndrome: a 6-month text-based observational study.
    Vrana-Diaz CJ; Balasubramanian P; Kayadjanian N; Bohonowych J; Strong TV
    Orphanet J Rare Dis; 2020 Sep; 15(1):233. PubMed ID: 32883323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial.
    Miller JL; Gevers E; Bridges N; Yanovski JA; Salehi P; Obrynba KS; Felner EI; Bird LM; Shoemaker AH; Angulo M; Butler MG; Stevenson D; Abuzzahab J; Barrett T; Lah M; Littlejohn E; Mathew V; Cowen NM; Bhatnagar A;
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1676-1685. PubMed ID: 36639249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nutritional intervention with hypocaloric diet for weight control in children and adolescents with Prader-Willi Syndrome.
    Lima VP; Emerich DR; Mesquita ML; Paternez AC; Carreiro LR; Pina Neto JM; Teixeira MC
    Eat Behav; 2016 Apr; 21():189-92. PubMed ID: 26970733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial.
    Hollander E; Levine KG; Ferretti CJ; Freeman K; Doernberg E; Desilva N; Taylor BP
    J Psychiatr Res; 2021 May; 137():643-651. PubMed ID: 33190843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study.
    Consoli A; Çabal Berthoumieu S; Raffin M; Thuilleaux D; Poitou C; Coupaye M; Pinto G; Lebbah S; Zahr N; Tauber M; Cohen D; Bonnot O
    Transl Psychiatry; 2019 Nov; 9(1):274. PubMed ID: 31685813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study.
    Strong TV; Miller JL; McCandless SE; Gevers E; Yanovski JA; Matesevac L; Bohonowych J; Ballal S; Yen K; Hirano P; Cowen NM; Bhatnagar A
    J Neurodev Disord; 2024 Apr; 16(1):22. PubMed ID: 38671361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report.
    Candler T; McGregor D; Narayan K; Moudiotis C; Burren CP
    J Pediatr Endocrinol Metab; 2020 Jul; 33(7):951-955. PubMed ID: 32447330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.
    Allas S; Caixàs A; Poitou C; Coupaye M; Thuilleaux D; Lorenzini F; Diene G; Crinò A; Illouz F; Grugni G; Potvin D; Bocchini S; Delale T; Abribat T; Tauber M
    PLoS One; 2018; 13(1):e0190849. PubMed ID: 29320575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcranial direct current stimulation reduces food-craving and measures of hyperphagia behavior in participants with Prader-Willi syndrome.
    Bravo GL; Poje AB; Perissinotti I; Marcondes BF; Villamar MF; Manzardo AM; Luque L; LePage JF; Stafford D; Fregni F; Butler MG
    Am J Med Genet B Neuropsychiatr Genet; 2016 Mar; 171B(2):266-75. PubMed ID: 26590516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome.
    Senda M; Ogawa S; Nako K; Okamura M; Sakamoto T; Ito S
    Endocr J; 2012; 59(10):889-94. PubMed ID: 22785236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
    Kelly AS; Auerbach P; Barrientos-Perez M; Gies I; Hale PM; Marcus C; Mastrandrea LD; Prabhu N; Arslanian S;
    N Engl J Med; 2020 May; 382(22):2117-2128. PubMed ID: 32233338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.
    Sani E; Prato GD; Zenti MG; Bordugo A; Trombetta M; Bonora E
    Endocr Metab Immune Disord Drug Targets; 2022; 22(10):1053-1057. PubMed ID: 35538810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review.
    Ng NBH; Low YW; Rajgor DD; Low JM; Lim YY; Loke KY; Lee YS
    Clin Endocrinol (Oxf); 2022 Feb; 96(2):144-154. PubMed ID: 34448208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years.
    Danne T; Biester T; Kapitzke K; Jacobsen SH; Jacobsen LV; Petri KCC; Hale PM; Kordonouri O
    J Pediatr; 2017 Feb; 181():146-153.e3. PubMed ID: 27979579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.